Posted On: 08/22/2016 9:15:22 AM
Post# of 83
BIGGGGGGGGGGGGGG NEWSSSSSSSSSSSSSS
and stock is stiill terrible underpriced at a market cap of laughable $52 Million .GL
http://www.intelgenx.com/investors/press-rele...fault.aspx
IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
August 22, 2016
"We are very pleased by the results of the study which confirmed that our Montelukast VersaFilm™ significantly improves the bioavailability of the drug when given as an oral film product. The study demonstrates that the VersaFilm™ technology is an effective delivery system for CNS applications," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "Montelukast is an important drug repurposing opportunity that the company has in its product pipeline which could potentially become a multi-billion-dollar product in the large and underserved market for degenerative diseases of the brain."
and stock is stiill terrible underpriced at a market cap of laughable $52 Million .GL
http://www.intelgenx.com/investors/press-rele...fault.aspx
IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
August 22, 2016
"We are very pleased by the results of the study which confirmed that our Montelukast VersaFilm™ significantly improves the bioavailability of the drug when given as an oral film product. The study demonstrates that the VersaFilm™ technology is an effective delivery system for CNS applications," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "Montelukast is an important drug repurposing opportunity that the company has in its product pipeline which could potentially become a multi-billion-dollar product in the large and underserved market for degenerative diseases of the brain."
(0)
(0)
